Merit Medical Systems MMSI Single Reportable — Research And Development Expense

Similar metrics at other companies

ALMSSingle Reportable — Research And Development Expense

$81.54M-15.6%

LNTHReportable — Research And Development Expense

$39.38M+8.4%

ACLSSingle Reportable — Research And Development Expense

$28.52M+5.1%

PLUGSingle Reportable — Research And Development Expense

$12.11M-30.2%

PCVXReportable Segment — R&D

$256.43M+147%

TVTXReportable Segment — R&D

$57.09M+21.8%

Other financials

Income statement

See full

Revenue$381.9M+7.5%

Gross profit$184.8M+7.4%

Operating income$44.2M+7.6%

Net income$41.0M+36.0%

EPS (diluted)$0.68+38.8%

Balance sheet

See full

Cash & equivalents$488.1M+23.4%

Total debt$821.6M+0.5%

Total equity$1.6B+13.9%

Total assets$2.7B+10.2%

Cash flow

See full

Operating cash flow$40.7M+0.3%

CapEx$16.0M-24.0%

Free cash flow$24.7M+26.5%

Valuation

See full

Market cap$4.01B-34.1%

Profitability

See full

Gross margin48.7%+0.9pp

Operating margin12.2%+0.6pp

Net margin9%+0.2pp

FCF margin14.3%+1.3pp

Returns & leverage

See full

Return on equity9.1%0.0pp

Debt / equity0.5×-0.1×

Current ratio5.1×+0.2×

Where this comes from

Reported directly by Merit Medical Systems in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Merit Medical Systems’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Merit Medical Systems's single reportable — research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Merit Medical Systems's single reportable — research and development expense?: Merit Medical Systems (MMSI) reported single reportable — research and development expense of $22.61M in Q1 2026.
What does single reportable — research and development expense mean?: This metric represents the investment in innovation, clinical trials, and the development of new medical technologies within the segment. It is a critical indicator of the company's commitment to long-term product pipeline growth and competitive differentiation. Investors monitor this to gauge the sustainability of the company's future revenue streams and technological leadership.